Literature DB >> 10467222

Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas?

S G Carruthers1.   

Abstract

Medical research has helped to clarify the benefits of some therapies for improving the treatment or outcome associated with cardiovascular disease. However, the adoption of these approaches into routine clinical practice is, in many cases, inadequate. Consequently, there are many missed opportunities to reduce the burden of morbidity and mortality from cardiovascular disease. This review summarizes the factors that may prevent modified behavior in medical practice and the effectiveness of interventions that influence change. There are many barriers that may prevent or slow the adoption of new therapeutic advances into routine clinical practice. As a result, the use of well-proven, efficacious therapy can be suboptimal. Because of this underuse, the realized benefits of treatment are below the potential benefits. Adoption of new therapies is highly dependent on the use of interventions to promote clinical change. However, the effectiveness of different types of interventions varies greatly. Nevertheless, there is a wide range of strategies available that can be used to induce real changes in practice performance and potentially improve patient outcomes. It is essential that future intervention strategies focus on improving adoption of new therapies into clinical practice. The physician must be encouraged to prescribe proven treatments to those patients who stand to benefit most. In addition, better systems of care should be developed that improve the identification of patients as suitable candidates for proven treatments and sustain their long-term commitment to therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467222     DOI: 10.1016/s0002-8703(99)70319-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Clinical relevance of the gap between pre-marketing trials and medical practice: the case of the cardiovascular drugs.

Authors:  N F Wieringa; P Denig; P A de Graeff; R Vos
Journal:  Neth Heart J       Date:  2002-11       Impact factor: 2.380

2.  Physician perceptions of primary prevention: qualitative base for the conceptual shaping of a practice intervention tool.

Authors:  Amy L Mirand; Gregory P Beehler; Christina L Kuo; Martin C Mahoney
Journal:  BMC Public Health       Date:  2002-08-30       Impact factor: 3.295

3.  Explaining the de-prioritization of primary prevention: physicians' perceptions of their role in the delivery of primary care.

Authors:  Amy L Mirand; Gregory P Beehler; Christina L Kuo; Martin C Mahoney
Journal:  BMC Public Health       Date:  2003-05-02       Impact factor: 3.295

4.  Experiences, expectations and challenges of an interactive mobile phone-based system to support self-management of hypertension: patients' and professionals' perspectives.

Authors:  Inger Hallberg; Agneta Ranerup; Ulrika Bengtsson; Karin Kjellgren
Journal:  Patient Prefer Adherence       Date:  2018-03-28       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.